VivoSeq
Hematology

Anemia, Sickle Cell

3

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Anemia, Sickle Cell is an early-stage landscape with 3 programs across 3 companies. The most active players are Bristol-Myers Squibb, Eli Lilly, Kenvue Brands.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

PreclinicalEli Lilly logo

Eli Lilly

1 program

PreclinicalK

Kenvue Brands

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical3

BMS-986470

Bristol-Myers Squibb

Famotidine

Kenvue Brands

Pantoprazole

Wyeth-Lederle Vaccines

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Preclinical·NCT06481306·224 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)